XTX Topco Ltd Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

XTX Topco Ltd bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 42,754 shares of the biotechnology company's stock, valued at approximately $384,000.

Several other large investors also recently added to or reduced their stakes in the company. State Street Corp raised its stake in Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock valued at $21,587,000 after purchasing an additional 64,949 shares during the period. Vanguard Group Inc. raised its stake in Aurinia Pharmaceuticals by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 1,729,948 shares of the biotechnology company's stock valued at $15,535,000 after purchasing an additional 112,113 shares during the period. Arrowstreet Capital Limited Partnership acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter valued at $9,662,000. JPMorgan Chase & Co. raised its stake in Aurinia Pharmaceuticals by 84.4% during the 4th quarter. JPMorgan Chase & Co. now owns 927,298 shares of the biotechnology company's stock valued at $8,327,000 after purchasing an additional 424,482 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Aurinia Pharmaceuticals by 44.0% during the 4th quarter. Renaissance Technologies LLC now owns 700,900 shares of the biotechnology company's stock valued at $6,294,000 after purchasing an additional 214,200 shares during the period. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Down 2.2 %

AUPH stock traded down $0.18 during mid-day trading on Monday, hitting $8.00. The stock had a trading volume of 1,250,882 shares, compared to its average volume of 1,348,428. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.92 and a 1-year high of $10.67. The company has a fifty day moving average of $8.00 and a 200 day moving average of $8.16. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -53.33 and a beta of 1.20.

Analyst Ratings Changes

Separately, StockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Insiders Place Their Bets

In other news, CEO Peter Greenleaf sold 195,593 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the transaction, the chief executive officer now owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at approximately $5,068,120. This represents a 8.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock valued at $2,753,094 in the last three months. Insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.